Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (2), 62-7

Multi-regional Clinical Trials and Global Drug Development

Affiliations
Review

Multi-regional Clinical Trials and Global Drug Development

Premnath Shenoy. Perspect Clin Res.

Abstract

Drug development has been globalized, and multi-regional clinical trial (MRCT) for regulatory submission has widely been conducted by many discovery based global pharmaceutical companies with the objective of reducing the time lag of launch in key markets and improve patient access to new and innovative treatments. Sponsors are facing several challenges while conducting multiregional clinical trials. Challenges under the heads statistics, clinical, regulatory operational, and ethics have been discussed. Regulators in different countries such as USA, EU-Japan, and China have issued guidance documents in respect of MRCT's. Lack of harmonization in the design and planning of MRCT is perceived to create a difficult situation to sponsors adversely affecting progressing MRCT in more and more discoveries. International conference on hormonisation (ICH) has initiated the process for having a harmonized guidance document on MRCT. This document is likely to be issued in early 2017.

Keywords: Clinical trials; United States of America Food and Drug Administration; international conference on harmonization; multi-regional.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

  • Cell-Based Therapies for Stroke: Are We There Yet?
    M Krause et al. Front Neurol 10, 656. PMID 31293500. - Review
    Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ische …

References

    1. Binkowitz B, Ibia E. Multiregional clinical trials: An introduction from an industry perspective. Ther Innov Regul Sci. 2011;45:569–73.
    1. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability – FDA. Notice. Fed Regist. 1998;63:31790–6. - PubMed
    1. Basic Principles on Global Clinical Trials, Notification No. 0928010, September 28th, 2007, JPMA (This Document is an Informal Translation by PMDA of the Final Notification Published in Japanese on September 28th, 2007 and is Intended to Use as a Reference for Considering Global Clinical Trials. 2007. [Last accessed on 2015 Aug 13]. Available from: https://www.pmda.go.jp/files/000157900.pdf .
    1. Reflection Paper on the Extrapolation of Results from Clinical Studies Conducted Outside of the EU to the EU Population, EMEA/CHMP/EWP/692702/2008. 2009. Oct 22nd, [Last accessed on 2015 Aug 13]. Available from: http://www.emea.europa.eu .
    1. Khin NA, Yang P, Hung HM, Maung KU, Chen YF, O'Connell M, et al. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: An FDA perspective. Clin Pharmacol Ther Genomic Med. 2013;94:230–42. - PubMed
Feedback